Monday, May 4, 2015

Study Links HIV to Eye Disease



Ethiopian ophthalmologist Dr. Tilahun Kiros examines a patient's eyes at the Quiha Eye Hospital Vision Center in Mekelle, Ethiopia.

A new study adds to growing evidence that HIV infected people have immune systems similar to those who are much older. This occurs even when they are being treated with antiretroviral drugs. The older-acting immune systems can make them more susceptible to certain diseases.

Dr. Douglas Jabs said while HIV/AIDS patients are living longer than ever – thanks to antiretroviral drugs – they are at greater risk of developing age-related diseases. These include cardiovascular disease, cancer, diabetes and even frailty.

Jabs is lead author of a new study that says they are also more susceptible to age-related macular degeneration or AMD. The disease can cause vision loss and blindness in its late stages. AMD is listed as the “leading cause of visual impairment and blindness in people over 65.” It causes damage to part of the retina called the macula, which is responsible for clear, sharp vision.

Jabs is a professor of both ophthalmology and medicine at the Icahn School of Medicine at Mount Sinai in New York.

He said, “There is an emerging body of data in the HIV literature that patients with HIV infection, who are treated with antiretroviral therapy and have immune recovery – so now they’re not getting opportunistic infections – they have markedly improved survivals – they all have a shortened survival relative to patients who are not HIV infected when you age match them.”

They appear to have – what’s called – accentuated or possibly accelerated aging.

“In addition, the immunologists are showing that the immune system of patients with HIV, who are treated with antiretroviral therapy and immune recovered, have changes similar to the immune systems of 75 year olds called immunosenescence,” he said.

Dr. Jabs and his colleagues studied more than 1,800 HIV patients between the ages of 13 and 73 from 1998 to 2011. The study says their immune systems were always activated and they had chronic inflammation – a condition that’s been linked to a number of health problems. In a sense, their immune systems had a lot of wear and tear.

“They’ve had a lot of immune stimulation. They’ve got a lot of cells that are responding to the things that they’ve seen. But they’re losing some of the ability to respond to new challenges. When with the immune activation they have systemic levels of inflammation using simple biomarkers. Those pieces of information suggested that because of the accelerated aging and because of the issues related to inflammation and immunosenescence that maybe patients who are HIV infected would have similar age-related changes in the eye. And so we decided to look for AMD,” he said.

When compared to a group of people of similar ages not infected with the AIDS virus they had a fourfold greater prevalence of macular degeneration.

‘We looked at all the different drugs they’re taking. It’s not related to the drugs. It’s not due to the drugs at all. It’s due to the beating the immune system has taken dealing with HIV and everything else. And it’s similar by the way to what the immune system looks like in a 75 year old adult, except these people are all 45,” he said.

The next step, said Dr. Jabs, is to try to understand what’s going on – to determine whether chronic activation of the immune system and systemic inflammation are actually the reasons for greater risk of AMD. In the meantime, he said the message is one of vigilance – manage diseases in HIV patents the way they would be treated in older individuals.

Study Links HIV to Eye Disease



Ethiopian ophthalmologist Dr. Tilahun Kiros examines a patient's eyes at the Quiha Eye Hospital Vision Center in Mekelle, Ethiopia.

A new study adds to growing evidence that HIV infected people have immune systems similar to those who are much older. This occurs even when they are being treated with antiretroviral drugs. The older-acting immune systems can make them more susceptible to certain diseases.

Dr. Douglas Jabs said while HIV/AIDS patients are living longer than ever – thanks to antiretroviral drugs – they are at greater risk of developing age-related diseases. These include cardiovascular disease, cancer, diabetes and even frailty.

Jabs is lead author of a new study that says they are also more susceptible to age-related macular degeneration or AMD. The disease can cause vision loss and blindness in its late stages. AMD is listed as the “leading cause of visual impairment and blindness in people over 65.” It causes damage to part of the retina called the macula, which is responsible for clear, sharp vision.

Jabs is a professor of both ophthalmology and medicine at the Icahn School of Medicine at Mount Sinai in New York.

He said, “There is an emerging body of data in the HIV literature that patients with HIV infection, who are treated with antiretroviral therapy and have immune recovery – so now they’re not getting opportunistic infections – they have markedly improved survivals – they all have a shortened survival relative to patients who are not HIV infected when you age match them.”

They appear to have – what’s called – accentuated or possibly accelerated aging.

“In addition, the immunologists are showing that the immune system of patients with HIV, who are treated with antiretroviral therapy and immune recovered, have changes similar to the immune systems of 75 year olds called immunosenescence,” he said.

Dr. Jabs and his colleagues studied more than 1,800 HIV patients between the ages of 13 and 73 from 1998 to 2011. The study says their immune systems were always activated and they had chronic inflammation – a condition that’s been linked to a number of health problems. In a sense, their immune systems had a lot of wear and tear.

“They’ve had a lot of immune stimulation. They’ve got a lot of cells that are responding to the things that they’ve seen. But they’re losing some of the ability to respond to new challenges. When with the immune activation they have systemic levels of inflammation using simple biomarkers. Those pieces of information suggested that because of the accelerated aging and because of the issues related to inflammation and immunosenescence that maybe patients who are HIV infected would have similar age-related changes in the eye. And so we decided to look for AMD,” he said.

When compared to a group of people of similar ages not infected with the AIDS virus they had a fourfold greater prevalence of macular degeneration.

‘We looked at all the different drugs they’re taking. It’s not related to the drugs. It’s not due to the drugs at all. It’s due to the beating the immune system has taken dealing with HIV and everything else. And it’s similar by the way to what the immune system looks like in a 75 year old adult, except these people are all 45,” he said.

The next step, said Dr. Jabs, is to try to understand what’s going on – to determine whether chronic activation of the immune system and systemic inflammation are actually the reasons for greater risk of AMD. In the meantime, he said the message is one of vigilance – manage diseases in HIV patents the way they would be treated in older individuals.

Thousands of Students Around the World Participate in Inaugural TOEFL® Young Students Series GO English! Project

Thousands of Students Around the World Participate in Inaugural TOEFL® Young Students Series GO English! Project

Thousands of Students Around the World Participate in Inaugural TOEFL® Young Students Series GO English! Project

Thousands of Students Around the World Participate in Inaugural TOEFL® Young Students Series GO English! Project

MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets

MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets

MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets

MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets

Securiport Announces Innovative Solutions as an INTERPOL World Strategic Partner at the Inaugural INTERPOL World 2015 Biennial Conference

Securiport Announces Innovative Solutions as an INTERPOL World Strategic Partner at the Inaugural INTERPOL World 2015 Biennial Conference

Securiport Announces Innovative Solutions as an INTERPOL World Strategic Partner at the Inaugural INTERPOL World 2015 Biennial Conference

Securiport Announces Innovative Solutions as an INTERPOL World Strategic Partner at the Inaugural INTERPOL World 2015 Biennial Conference

Samsung Outlines Approach for Smart Lighting at LIGHTFAIR International 2015

Samsung Outlines Approach for Smart Lighting at LIGHTFAIR International 2015

Samsung Outlines Approach for Smart Lighting at LIGHTFAIR International 2015

Samsung Outlines Approach for Smart Lighting at LIGHTFAIR International 2015

Sunday, May 3, 2015

10 sea Creatures You Won't Believe Exist

https://www.youtube.com/watch?v=pGBNLxPMhhI

some times we believe things by naked eyes. But some times we do not accept without evidence.

10 sea Creatures You Won't Believe Exist

https://www.youtube.com/watch?v=pGBNLxPMhhI

some times we believe things by naked eyes. But some times we do not accept without evidence.

15 Things You Didn't Know About Earth

https://www.youtube.com/watch?v=u9A_HSO1TnA

It is nature. man then tries to change it every minute, but finally nature wins over man.

15 Things You Didn't Know About Earth

https://www.youtube.com/watch?v=u9A_HSO1TnA

It is nature. man then tries to change it every minute, but finally nature wins over man.

Planet Earth 100 Million Years In The Future - What will happen to our world?

https://www.youtube.com/watch?v=uQ91AxUqHck&sns=tw

watch carefully and think about the ways that we follow to save world to be lived long long years.
give a contribution by your activities make the world to be lived long days healthy.

Planet Earth 100 Million Years In The Future - What will happen to our world?

https://www.youtube.com/watch?v=uQ91AxUqHck&sns=tw

watch carefully and think about the ways that we follow to save world to be lived long long years.
give a contribution by your activities make the world to be lived long days healthy.

Saturday, May 2, 2015

Fun fun fun...........100% dont miss;;;; dont try it own

https://www.facebook.com/Rmbds/videos/1132406770111257/?pnref=story

Fun fun fun...........100% dont miss;;;; dont try it own

https://www.facebook.com/Rmbds/videos/1132406770111257/?pnref=story

Drugs that activate brain stem cells may reverse multiple sclerosis

NIH-funded study identifies over-the-counter compounds that may replace damaged cells

Two drugs already on the market — an antifungal and a steroid — may potentially take on new roles as treatments for multiple sclerosis. According to a study published in Nature today, researchers discovered that these drugs may activate stem cells in the brain to stimulate myelin producing cells and repair white matter, which is damaged in multiple sclerosis. The study was partially funded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health.



An artist’s representation of the study. Scientists found that certain drugs were able to promote remyelination in mouse models of multiple sclerosis. Image courtesy of Case Western Reserve University; Illustrator: Megan Kern

Specialized cells called oligodendrocytes lay down multiple layers of a fatty white substance known as myelin around axons, the long “wires” that connect brain cells. Myelin acts as an insulator and enables fast communication between brain cells. In multiple sclerosis there is breakdown of myelin and this deterioration leads to muscle weakness, numbness and problems with vision, coordination and balance.

“To replace damaged cells, the scientific field has focused on direct transplantation of stem cell-derived tissues for regenerative medicine, and that approach is likely to provide enormous benefit down the road. We asked if we could find a faster and less invasive approach by using drugs to activate native nervous system stem cells and direct them to form new myelin. Our ultimate goal was to enhance the body’s ability to repair itself,” said Paul J. Tesar, Ph.D., associate professor at Case Western Reserve School of Medicine in Cleveland, and senior author of the study.

It is unknown how myelin-producing cells are damaged, but research suggests they may be targeted by malfunctioning immune cells and that multiple sclerosis may start as an autoimmune disorder. Current therapies for multiple sclerosis include anti-inflammatory drugs, which help prevent the episodic relapses common in multiple sclerosis, but are less effective at preventing long-term disability. Scientists believe that therapies that promote myelin repair might improve neurologic disability in people with multiple sclerosis. 

Adult brains contain oligodendrocyte progenitor cells (OPCs), which are stem cells that generate myelin-producing cells. OPCs are found to multiply in the brains of multiple sclerosis patients as if to respond to myelin damage, but for unknown reasons they are not effective in restoring white matter. In the current study, Dr. Tesar wanted to see if drugs already approved for other uses were able to stimulate OPCs to increase myelination. 

OPCs have been difficult to isolate and study, but Dr. Tesar and his colleagues, in collaboration with Robert Miller, Ph.D., professor at George Washington University School of Medicine and Health Sciences in Washington, D.C., developed a novel method to investigate these cells in a petri dish. Using this technique, they were able to quickly test the effects of hundreds of drugs on the stem cells.

The compounds screened in this study were obtained from a drug library maintained by NIH’s National Center for Advancing Translational Sciences (NCATS). All are approved for use in humans. NCATS and Dr. Tesar have an ongoing collaboration and plan to expand the library of drugs screened against OPCs in the near future to identify other promising compounds.

Dr. Tesar’s team found that two compounds in particular, miconazole (an antifungal) and clobetasol (a steroid), stimulated mouse and human OPCs into generating myelin-producing cells.

Next, they examined whether the drugs, when injected into a mouse model of multiple sclerosis, could improve re-myelination. They found that both drugs were effective in activating OPCs to enhance myelination and reverse paralysis. As a result, almost all of the animals regained the use of their hind limbs. They also found that the drugs acted through two very different molecular mechanisms. 

“The ability to activate white matter cells in the brain, as shown in this study, opens up an exciting new avenue of therapy development for myelin disorders such as multiple sclerosis,” said Ursula Utz, Ph.D., program director at the NINDS.

Dr. Tesar and his colleagues caution that more research is needed before miconazole and clobetasol can be tested in multiple sclerosis clinical trials. They are currently approved for use as creams or powders on the surfaces of the body but their safety administered in other forms, such as injections, in humans is unknown.

“Off-label use of the current forms of these drugs is more likely to increase other health concerns than alleviate multiple sclerosis symptoms. We are working tirelessly to ready a safe and effective drug for clinical use,” Dr. Tesar said.

This work was supported by the NINDS (NS085246, NS030800, NS026543), the New York Stem Cell Foundation and the Myelin Repair Foundation, New York City.

The NINDS is the nation’s leading funder of research on the brain and nervous system. The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

The National Center for Advancing Translational Sciences is a distinctly different entity in the research ecosystem. Rather than targeting a particular disease or fundamental science, NCATS focuses on what is common across diseases and the translational process. The Center emphasizes innovation and deliverables, relying on the power of data and new technologies to develop, demonstrate and disseminate advancements in translational science that bring about tangible improvements in human health. For more information, visit http://www.ncats.nih.gov.

Drugs that activate brain stem cells may reverse multiple sclerosis

NIH-funded study identifies over-the-counter compounds that may replace damaged cells

Two drugs already on the market — an antifungal and a steroid — may potentially take on new roles as treatments for multiple sclerosis. According to a study published in Nature today, researchers discovered that these drugs may activate stem cells in the brain to stimulate myelin producing cells and repair white matter, which is damaged in multiple sclerosis. The study was partially funded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health.



An artist’s representation of the study. Scientists found that certain drugs were able to promote remyelination in mouse models of multiple sclerosis. Image courtesy of Case Western Reserve University; Illustrator: Megan Kern

Specialized cells called oligodendrocytes lay down multiple layers of a fatty white substance known as myelin around axons, the long “wires” that connect brain cells. Myelin acts as an insulator and enables fast communication between brain cells. In multiple sclerosis there is breakdown of myelin and this deterioration leads to muscle weakness, numbness and problems with vision, coordination and balance.

“To replace damaged cells, the scientific field has focused on direct transplantation of stem cell-derived tissues for regenerative medicine, and that approach is likely to provide enormous benefit down the road. We asked if we could find a faster and less invasive approach by using drugs to activate native nervous system stem cells and direct them to form new myelin. Our ultimate goal was to enhance the body’s ability to repair itself,” said Paul J. Tesar, Ph.D., associate professor at Case Western Reserve School of Medicine in Cleveland, and senior author of the study.

It is unknown how myelin-producing cells are damaged, but research suggests they may be targeted by malfunctioning immune cells and that multiple sclerosis may start as an autoimmune disorder. Current therapies for multiple sclerosis include anti-inflammatory drugs, which help prevent the episodic relapses common in multiple sclerosis, but are less effective at preventing long-term disability. Scientists believe that therapies that promote myelin repair might improve neurologic disability in people with multiple sclerosis. 

Adult brains contain oligodendrocyte progenitor cells (OPCs), which are stem cells that generate myelin-producing cells. OPCs are found to multiply in the brains of multiple sclerosis patients as if to respond to myelin damage, but for unknown reasons they are not effective in restoring white matter. In the current study, Dr. Tesar wanted to see if drugs already approved for other uses were able to stimulate OPCs to increase myelination. 

OPCs have been difficult to isolate and study, but Dr. Tesar and his colleagues, in collaboration with Robert Miller, Ph.D., professor at George Washington University School of Medicine and Health Sciences in Washington, D.C., developed a novel method to investigate these cells in a petri dish. Using this technique, they were able to quickly test the effects of hundreds of drugs on the stem cells.

The compounds screened in this study were obtained from a drug library maintained by NIH’s National Center for Advancing Translational Sciences (NCATS). All are approved for use in humans. NCATS and Dr. Tesar have an ongoing collaboration and plan to expand the library of drugs screened against OPCs in the near future to identify other promising compounds.

Dr. Tesar’s team found that two compounds in particular, miconazole (an antifungal) and clobetasol (a steroid), stimulated mouse and human OPCs into generating myelin-producing cells.

Next, they examined whether the drugs, when injected into a mouse model of multiple sclerosis, could improve re-myelination. They found that both drugs were effective in activating OPCs to enhance myelination and reverse paralysis. As a result, almost all of the animals regained the use of their hind limbs. They also found that the drugs acted through two very different molecular mechanisms. 

“The ability to activate white matter cells in the brain, as shown in this study, opens up an exciting new avenue of therapy development for myelin disorders such as multiple sclerosis,” said Ursula Utz, Ph.D., program director at the NINDS.

Dr. Tesar and his colleagues caution that more research is needed before miconazole and clobetasol can be tested in multiple sclerosis clinical trials. They are currently approved for use as creams or powders on the surfaces of the body but their safety administered in other forms, such as injections, in humans is unknown.

“Off-label use of the current forms of these drugs is more likely to increase other health concerns than alleviate multiple sclerosis symptoms. We are working tirelessly to ready a safe and effective drug for clinical use,” Dr. Tesar said.

This work was supported by the NINDS (NS085246, NS030800, NS026543), the New York Stem Cell Foundation and the Myelin Repair Foundation, New York City.

The NINDS is the nation’s leading funder of research on the brain and nervous system. The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

The National Center for Advancing Translational Sciences is a distinctly different entity in the research ecosystem. Rather than targeting a particular disease or fundamental science, NCATS focuses on what is common across diseases and the translational process. The Center emphasizes innovation and deliverables, relying on the power of data and new technologies to develop, demonstrate and disseminate advancements in translational science that bring about tangible improvements in human health. For more information, visit http://www.ncats.nih.gov.

SELFAA is ready to come in 2026